P
ALT icon

&Partners’s Altimmune ALT Stock Holding History

&Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,035
Closed -$54.3K – 2400
2025
Q4 		$54.3K Buy
+15,035
New +$65.5K ﹤0.01% 2241

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

&Partners's ALT Position: Q1 2026 in Review

&Partners sold out of Altimmune (ALT) in Q1 2026, closing a stake of 15,035 shares — an estimated $54.3K sold.

&Partners first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $54.3K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • &Partners reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • &Partners sold 15,035 Altimmune shares in Q1 2026, an estimated $54.3K.
  • &Partners first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
  • &Partners's Altimmune position peaked at $54.3K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.